US5315015A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
Assignee: Roche Diagnostics Corp
•
Filing: 1992-11-10
•
Granted: 1994-05-24
•
Expires: 2012-11-10
Abstract
Abstract Compounds of the formula <IMAGE> I wherein F is a fluorescing compound; Y is -NH- or a single covalent bond; Z is a straight or branched alkylene chain of 2 to 10 carbon atoms which is substituted by at least one hydrophilic group; Q is oxygen or sulfur; and X is a ligand-analog, the ligand-analog capable of being recognized by an antibody specific to the corresponding ligand. These compounds have improved properties in fluorescence polarization immunoassays by possessing either a better intensity and/or a larger span.
Inventors
- 👤 Raymond A. Hui
- 👤 Kathryn S. Schwenzer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 05:39
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/94; G01N33/58; G01N33/582
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
64 words
A compound of the formula: ##STR12## wherein F is a fluorescent group; Y is --NH-- or a single covalent bond; Z is straight or branched alkylene chain of two to ten carbon atoms which is substituted with at least one hydrophilic group; Q is oxygen or sulfur; and X is a ligand-analog capable of being recognized by an antibody specific to the corresponding ligand.
Claim 2
Dependent Claim
64 words
A compound of the formula: ##STR12## wherein F is a fluorescent group; Y is --NH-- or a single covalent bond; Z is straight or branched alkylene chain of two to ten carbon atoms which is substituted with at least one hydrophilic group; Q is oxygen or sulfur; and X is a ligand-analog capable of being recognized by an antibody specific to the corresponding ligand.
Claim 3
Dependent Claim
12 words
The compound according to claim 1, wherein X is a tetrahydrocannabinoid analog.
Claim 4
Dependent Claim
12 words
The compound according to claim 1, wherein X is a carbamazepine analog.
Claim 5
Dependent Claim
12 words
The compound according to claim 1, wherein X is a phenytoin analog.
Claim 6
Dependent Claim
35 words
The compound according to claim 1, wherein the polar hydrophilic group is selected from the group consisting of hydroxy, carboxy, carboxylate esters, carbamyl, thiocarbamyl, amino, substituted amino, sulfino, sulfo, sulfamyl, phosphono, nitro, hydroxyalkoxy, or aminoalkoxy.
Claim 7
Dependent Claim
21 words
The compound according to claim 2, wherein Y is a single covalent bond; Q is oxygen; and Z is 2-hydroxy propylene.
Claim 8
Dependent Claim
14 words
The compound according to claim 2, wherein Y is --NH--, and Q is oxygen.
Claim 9
Dependent Claim
12 words
The compound according to claim 5, wherein the tetrahydrocannabinoid analog is 6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6H-dibenzo[b,d]pyran-9-yl.
Claim 10
Dependent Claim
12 words
The compound according to claim 5, wherein the tetrahydrocannabinoid analog is 6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6H-dibenzo[b,d]pyran-9-yl.
Claim 11
Dependent Claim
10 words
The compound according to claim 1, wherein F is 5-fluoresceinyl.
Claim 12
Dependent Claim
10 words
The compound according to claim 1, wherein F is 6-fluoresceinyl.
Claim 13
Dependent Claim
10 words
The compound according to claim 6, wherein F is 5-fluoresceinyl.
Claim 14
Dependent Claim
10 words
The compound according to claim 6, wherein F is 6-fluoresceinyl.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-05-23 | 1997-11-22 | 1998-05-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-05-23 | 2001-11-22 | 2002-05-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-05-23 | 2005-11-22 | 2006-05-24 | $7700.00 | Window Closed / Lapsed |